- Home
- LUCY vs BOLT Comparison
LUCY vs BOLT Comparison
Compare LUCY & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | BOLT |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LUCY | BOLT |
|---|---|---|
| Price | $0.72 | $3.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 215.0K | 20.9K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,661,669.00 | ★ $7,695,000.00 |
| Revenue This Year | $175.92 | N/A |
| Revenue Next Year | $205.56 | $133.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 62.65 | 0.07 |
| 52 Week Low | $0.65 | $3.13 |
| 52 Week High | $2.24 | $7.20 |
Technical Indicators
Market Signals| Indicator | LUCY | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 32.89 |
| Support Level | $0.66 | N/A |
| Resistance Level | $1.17 | $4.46 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 50.72 | 26.47 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.